A selection of current clinical trials is reported in Table 2. Few attempts are underway to exploit specific defects in apoptosis and necroptosis of NB cells.
In light of this, current clinical studies are focused on investigating TNBC for response to agents that are believed to exploit HR defects, including platinum agents and poly (ADP-ribose) polymerase inhibitors.
Because cancer drugs are small enough to slip through these holes, they can exploit this defect — but they also need a strategy to cross the blood-brain barrier in order to reach the tumor.
It's a line that continues to resonate: the deeper Cohle wades into the Dora Lange murder, the more we see of his particular skill for finding and exploiting the defects in those around him.
In this work, we achieve a 3-fold increase in the multiplexing capacity of the DiLeu reagent without increasing structural complexity by exploiting mass defects that arise from selective incorporation of C, N, and H stable isotopes in the reporter group.
So many of the financial schemes that led us astray over the past decade exploit precisely these defects in our decision-making tools.
Poly(ADP-ribose) polymerase-1 (PARP) inhibitors (PARPi) exploit tumour-specific defects in homologous recombination DNA repair and continuous dosing is most efficacious.
Such a marker could also potentially serve as a target for drugs designed to seek out and exploit specific molecular defects in cancerous cells.
Genome stability genes, such as TP53, ATM, BRCA1, BRCA2, and MSH2, are frequently mutated in tumors and many current antitumor therapeutics exploit genome stability defects through the use of DNA-damaging genotoxic agents (Helleday et al. 2008).
Related to this, patients with inherited germline mutations in BRCA2 and related genes now have options for chemotherapeutic management that exploit their cancers' defects in DNA damage repair, for example mitomycin C or PARP inhibitors [ 61, 68, 69].
